Vesper Bio secures $873K grant from Michael J. Fox Foundation
Click Here to Manage Email Alerts
A clinical stage biotech company has been awarded a grant for $873,000 by The Michael J. Fox Foundation for Parkinson’s Research to help assess sortilin inhibition in Parkinson’s disease.
According to a release from Vesper Bio, the grant was awarded under the foundation’s Pipeline Program, which aims to fund therapeutic development that prevents, slows or stops disease progression as well as to advance preclinical testing of promising therapeutic developments that address unmet medical needs in those with PD.
The project is expected to commence by the end of the month, per the release.
“Vesper has developed orally administered, small molecule, sortilin inhibitors that elevate central progranulin levels and these hold promise for treating certain CNS diseases, including Parkinson’s disease,” Anders Nykjaer, MD, PhD, Vesper Bio’s chief scientific officer, said in the release, This grant will support our research as we look to further demonstrate the efficacy of this novel therapy against this terrible disease.”
Vesper is currently expediting the development of VES001 for GRN frontotemporal dementia through ongoing phase 1 studies that will include a phase 1b proof-of-concept in GRN mutation carriers in advance of potentially registrational phase 2/3 trials.